1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Cboe Europe  -  04:50 2022-08-10 am EDT
765.30 DKK   -0.14%
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associated persons
GL
08/08NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associated persons
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : UBS lowers its rating to Sell

06/28/2022 | 03:32am EDT

UBS is revising its board downwards. The broker is now advising to sell against neutral previously. Previously set at DKK 630, the target price has been raised to DKK 700.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
08/08NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
08/05PUMP / DUMP #40 : This week's gainers and losers
MS
08/05NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
08/05TRANSCRIPT : Novo Nordisk A/S, Q2 2022 Earnings Call, Aug 05, 2022
CI
08/05NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
08/05NOVO NORDISK : Buy rating from Deutsche Bank
MD
08/05NOVO NORDISK : Receives a Sell rating from Jefferies
MD
08/04GLOBAL MARKETS LIVE : Bayer, Merck, eBay, MetLife, Eli Lilly...
MS
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 171 B 23 508 M 23 508 M
Net income 2022 54 404 M 7 475 M 7 475 M
Net cash 2022 1 229 M 169 M 169 M
P/E ratio 2022 31,4x
Yield 2022 1,55%
Capitalization 1 737 B 239 B 239 B
EV / Sales 2022 10,1x
EV / Sales 2023 8,87x
Nbr of Employees 50 816
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 766,40 DKK
Average target price 827,04 DKK
Spread / Average Target 7,91%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S4.27%238 658
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976